Why Medical Rehabilitation Is Leading the Next Wave of Brain-Computer Interfaces

Brain-computer interfaces are widening beyond the familiar EEG cap. Researchers and companies are combining electrical, hemodynamic and imaging signals, while exploring ultrasound and closed-loop stimulation to improve spatial targeting or influence deeper brain regions.

That expansion does not mean EEG is about to disappear. Scalp EEG still offers a practical combination of temporal resolution, portability, relatively low cost and reusability. Its weaknesses—low spatial resolution, limited signal-to-noise ratio and sensitivity to motion and muscle artifacts—are instead pushing the industry toward multimodal systems. 505153

The commercial implication is important: the first major scalable market is more likely to be clinically supervised rehabilitation than consumer “mind control.”

The BCI landscape: precision versus practicality

BCI systems are often grouped by how they acquire neural signals and whether they require a procedure.

Invasive interfaces

Intracortical systems place electrodes into brain tissue. They can capture activity from small neuronal populations and offer the highest signal specificity, supporting demanding control tasks. The trade-off is substantial: implantation requires neurosurgery, and system maintenance or removal is not a casual or reversible process.

Semi-invasive interfaces

ECoG and epidural or subdural electrodes sit on or near the brain’s surface rather than recording through the scalp. They can reduce some of the signal attenuation associated with EEG while avoiding penetration of the cortex in some designs. They still require surgery, carry procedural risks and cover only the implanted region. 49

Functional ultrasound is another example of why the boundaries can be confusing. fUS can provide detailed hemodynamic information and has been used in high-resolution motor-decoding research, but the strongest demonstrations commonly depend on an epidural setup, a cranial window or an acoustically transparent skull prosthesis. It should therefore not be treated as a ready-to-wear consumer replacement for EEG. 505859

Non-invasive interfaces

Non-invasive systems record or stimulate without opening the skull. Examples include EEG, fNIRS, MEG, fMRI and emerging transcranial ultrasound or electrical-stimulation systems.

Their practical advantages are safety, repeat use and easier deployment. Their limitations vary by modality:

• EEG: fast electrical measurements and good portability, but weak spatial specificity and vulnerability to artifacts.
• fNIRS: portable hemodynamic sensing, but slower responses and limited depth.
• MEG: strong temporal information, but expensive, environmentally sensitive and generally non-portable.
• fMRI: high anatomical and spatial detail across the brain, but slow relative to EEG, costly, bulky and poorly suited to movement or everyday control. 51525560
• Transcranial ultrasound and temporal-interference stimulation: promising approaches for reaching deeper targets without implants, but still subject to technical, safety and clinical-validation constraints. 18242756

In short, the choice is not simply “more accurate” versus “less accurate.” It is a system-level decision involving signal quality, surgical burden, portability, setup time, reliability, cost and the clinical value of the output.

Why EEG still matters

EEG signals are weakened and blurred as they pass through the skull and tissue. This limits spatial resolution and information transfer, while movement, facial muscles, sweat and electrical interference can degrade performance. 5054

Even so, EEG has a powerful deployment advantage: the same headset can be used repeatedly, moved between patients under appropriate hygiene protocols and integrated into a clinic or home program without an implant procedure. That makes it especially suitable when the goal is not to decode every individual movement, but to detect a limited set of motor intentions or brain states and connect them to therapy.

The industry’s likely direction is therefore multimodal rather than post-EEG. EEG may be combined with fNIRS, eye tracking, electromyography, inertial sensors, physiological data or imaging so that each channel compensates for the others’ weaknesses. 5354

Where the commercial opportunities are

Medical rehabilitation is the strongest near-term case

Rehabilitation has clearer users, workflows and outcome measures than most consumer applications. Stroke, spinal-cord injury, traumatic brain injury and other motor impairments provide clinically meaningful endpoints such as hand function, gait, activities of daily living and therapy adherence.

A non-invasive BCI can translate detected motor intent into feedback through functional electrical stimulation, a robotic device, an exoskeleton, a rehabilitation game or a therapist-guided visual interface. China’s BCI clinical landscape illustrates this concentration: a 2026 analysis found that non-invasive systems represented 79.1% of registered studies, while stroke rehabilitation was the leading indication at 65.0%. 1

Industry reporting also identifies rehabilitation as a likely source of significant business value over the next two to three years, citing the size of the patient population and the relative maturity of non-invasive BCI technology. That is a forecast, not proof of market success, but it aligns with the clinical-trial pattern. 4

Sleep and brain-state management are promising but evidence-limited

Portable polysomnography, EEG sleep staging, fatigue monitoring, neurofeedback and closed-loop auditory stimulation offer plausible commercial entry points as monitoring or wellness products.

Researchers are also studying temporal-interference stimulation, transcranial ultrasound and adaptive stimulation systems that respond to ongoing sleep activity. These approaches may eventually support more targeted neuromodulation. However, a review of non-invasive brain stimulation in sleep medicine concluded that no such approach yet has sufficient evidence to be recommended as a treatment for a sleep disorder. 18

That distinction matters for product positioning. A device that measures sleep or demonstrates a physiological change is not automatically a clinically validated treatment. Regulatory claims, trial design and long-term outcomes will determine whether these systems remain wellness tools or become medical products.

Human-computer interaction will develop in segments

For healthy users, BCI must outperform voice, gaze, gesture, electromyography and conventional interfaces on accuracy, comfort, calibration time and price. EEG’s variability across users and sessions makes that a difficult standard. 5354

The opportunity is stronger where conventional input is unavailable or impractical:

1. Severe paralysis: even a low-bandwidth but reliable interface can improve communication, autonomy and environmental control when speech, limb movement or eye control is limited.
2. Hands-occupied industrial work: BCI could help confirm alerts, request information or switch modes, but safety-critical systems cannot tolerate frequent false activations.
3. AR and VR: brain-state signals could add information about workload, fatigue, attention or coarse intent to gaze and hand tracking rather than replace them.
4. Robots and embodied AI: the most credible long-term role is a supervisory channel for high-level intent, preferences and corrections. Vision and context can handle routine actions while BCI supplies human oversight.

These are not equally mature markets. Assistive communication has an urgent unmet need; industrial and immersive applications require robust multimodal interaction; general-purpose thought control remains a much higher technical and commercial bar.

What the Neuracle evidence shows—and does not show

The available sources support a significant distinction in Neuracle’s story. In March 2026, China’s National Medical Products Administration approved the company’s NEO implantable hand-motor-function compensation system, described by the reporting sources as the first implantable BCI Class III medical device to receive market approval. 334243

That is an invasive or minimally invasive clinical milestone, not evidence by itself that Neuracle led China’s 2025 non-invasive EEG rehabilitation market. One later report states that the company’s 2025 revenue came from non-invasive EEG products sold to hospitals and research institutions, but the available evidence does not independently establish the requested market-leadership claim, a definitive customer list or a complete set of registrations. 41

A claim such as “domestic market leader” also needs a defined denominator: revenue, installed systems, hospital customers, regulatory registrations, rehabilitation sessions or tender wins. Without that definition and an auditable source, it should be treated as a company or market-position assertion rather than a verified conclusion.

The supplied evidence likewise does not substantiate specific MindMatrices products or a verified roadmap covering portable polysomnography, temporal-interference deep-brain stimulation and closed-loop sleep intervention. Those claims would require confirmation through regulatory records, clinical-trial registries, peer-reviewed publications or dated company disclosures.

Five gates for a scalable rehabilitation market

Medical rehabilitation has the strongest path to scale, but the industry still has to clear five practical gates.

1. Engineering stability

Devices must produce consistent signals across days, users, hair types, sweat, movement and clinical sites. Setup, electrode placement and recalibration must become fast enough for real workflows. A safe system also needs predictable behavior when the signal is ambiguous—not merely high accuracy under laboratory conditions.

2. Clinical evidence

Task decoding is not the same as rehabilitation efficacy. Products need adequately powered, preferably multicentre controlled studies showing improvement beyond standard therapy, with outcomes that persist in daily function and quality of life.

3. Regulation and reimbursement

A defined intended use, manufacturing quality, safety evidence, cybersecurity controls and clinician integration are prerequisites for medical deployment. Reimbursement must also cover the hardware, setup, staff time and follow-up required to deliver the intervention.

4. Retention and economics

Patients and therapists must tolerate the device over weeks, not just during a demonstration. Complicated caps, long calibration sessions, technician requirements, high hardware costs and weak adherence at home can eliminate the value of an otherwise effective system.

5. Data governance

Neural and behavioral data require explicit consent, data minimization, encryption, access controls, retention limits and clear rules for model updates and secondary use. Protections are particularly important where employers, insurers or platforms could use brain-related data to infer sensitive characteristics.

The bottom line

BCI is expanding beyond scalp EEG, but the next phase is likely to be defined by practical combinations of technologies rather than a single successor modality. fMRI offers spatial richness without portability; fUS offers intriguing precision but still faces major access and hardware constraints; semi-invasive systems improve signal quality at the cost of a procedure; and EEG remains the most deployable foundation for repeated, supervised use.

That is why rehabilitation is the leading candidate for non-invasive BCI’s first large-scale market. The winning product will not be the one that produces the most impressive laboratory demo. It will be the one that reliably improves patient function, fits clinical and home workflows, earns regulatory and payment support, retains users and protects the data generated along the way.